GICC has already gone to Japan to carry out the technical transfer of immune cell preparations, and will strive to connect the medical end by the end of the year.

The Ministry of Health and Welfare announced on September 6 that it would open up immunocellular therapy to the public. GICC Group sent the first batch of research teams led by PhD researchers to Japan to carry out the technology transfer of HITV immunotherapy in Japan's Lotus Medical Clinic and hopes to set up an official Taiwan laboratory in October to cultivate Taiwan's own research team to carry out the cultivation of immunocellular therapy.

Bohui Biotech's Chairman, Mr. Guo Jingyao, said, "The degree of openness of the Special Administrative Law this time is very high, and *** to cancer patients to give quite a lot of support, but also so that the Taiwan has a better basis for investment in the development of immunotherapy," he said.

?

According to Dr. Wang Zhenyu, who is in Japan, Japan has a free diagnosis and treatment system, so the international community is still waiting to see if autoimmune cell therapy will be effective. Many research institutions in Japan have accumulated decades of experience in research and development and application, and the technology is relatively mature compared to other countries. The immune cell therapy for advanced cancer patients, in the absence of drugs available in the situation still have good therapeutic results, in addition to Dr. Wang also relayed the Japanese physician's statement, Taiwan every year at their own expense to Japan to receive immunotherapy more than a hundred people.

Taiwan is now open to immune cell therapy, from the original stage 4 cancer patients, open to 1-3 patients who have not been treated with existing drugs can also apply for use. After the development of the management approach, patients will soon be able to receive accredited medical institutions in their own country to carry out immunotherapy, but also to put an end to the informal therapy of the past clinics privately provided by the patients and their families to obtain more protection.

"The more people invest in the immune-cell industry, the more the cancer immunotherapy industry will really develop, and whether or not a patient is using HITV immunotherapy, it's a good therapy as long as it's beneficial to the cancer patient. As long as it is beneficial to cancer patients, it is a good therapy." Guo Jingyao explained that there are many different types of immunotherapy in Japan, and no single therapy can cure all diseases. The HITV therapy introduced by Bohui Biotech is mainly applied to solid tumors, but there are still many types of cancers that require the input of biotech medical professionals to break through the current bottlenecks, and Bohui Biotech will continue to make efforts in the future to target different cancers in the hope that it can serve more cancer patients.